Q-omics provides the consensus-scored HDGFL3P1 profile across patient tissues and cancer cell-line models. HDGFL3P1 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, HDGFL3P1 is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, HDGFL3P1 RNA expression shows 5,809 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, UCEC, and STAD as cancer lineages where HDGFL3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HDGFL3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HDGFL3P1 survival associations across molecular data types. HDGFL3P1 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HDGFL3P1 RNA expression–survival associations across cancer types. High HDGFL3P1 expression shows unfavorable associations in THCA, BLCA, CHOL, LIHC and UCEC, but favorable associations in LUSC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for HDGFL3P1 RNA expression.
This table summarizes HDGFL3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for HDGFL3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HDGFL3P1 shows higher tumor expression in UCEC, KIRP, ESCA and LIHC. The UCEC box plot shows higher HDGFL3P1 RNA expression in tumor versus normal tissue (log2 FC = +0.088, t-test p = .019).
This table shows molecular features associated with HDGFL3P1 in patient tissues and cancer cell lines. In patient samples, HDGFL3P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
